Researchers create record-sized, integrated cellular cancer database

Investigators in CCR have consolidated and expanded some of the world’s largest cancer databases to create an integrated, comprehensive cellular databank. The publicly available tool, called CellMinerCDB, can be used to explore in unprecedented detail the relationship between drugs, mutations, copy number, methylation and gene and protein expression. Read more...

Steven Pavletic

Steven Pavletic elected as corresponding member of the Croatian Academy of Arts and Sciences

Jun 28, 2018

Steven Pavletic, M.D., Senior Clinician in the Experimental Transplantation and Immunology Branch, has been elected as a corresponding member of the Croatian Academy of Sciences and Arts. Dr. Pavletic was honored during a ceremony on June 14 at the Palace of the Academy in Zagreb, Croatia. Read more...

Steven Pavletic elected as corresponding member of the Croatian Academy of Arts and Sciences
Multiple myeloma

CAR T-cell therapy proves effective against multiple myeloma

Jun 27, 2018

A first-in-human clinical trial of multiple myeloma-targeted CAR T cells produced remissions in patients with advanced disease who had received numerous prior treatments. Read more...

DLBCL

Protein complex could be key to drug responsiveness in lymphoma patients

Jun 26, 2018

Continuing a decades-long refinement in understanding how and why a drug is more effective in some patients with lymphoma than others has led to the discovery of a complex of proteins that affects drug responsiveness. Read more...

Killer T cell

CCR: A history of advancing the field of immunology

Jun 26, 2018

The Center for Cancer Research has been at the forefront in the field of immunology and immunotherapy for decades. Our scientists have made seminal findings that have opened doors to new research areas and treatment approaches for cancer patients. Use this timeline to explore our rich history at the cutting edge of research towards understanding the immune system and harnessing its power to treat cancer. Read more...

CCR: A history of advancing the field of immunology
immunotherapy

Clinical trial tests combinations of immunotherapy drugs for prostate cancer

Jun 20, 2018

Metastatic castration-resistant prostate cancer (mCRPC) is a disease that has spread beyond the prostate and no longer responds to hormone therapy. James Gulley, M.D., Ph.D., of the Genitourinary Malignancies Branch is leading a study of combination immunotherapy where patients will be treated with two, three or four drugs that affect the immune system in different ways to determine the safety of various combinations and whether they can make tumors shrink. Read more...

Facebook Live: Pediatric and Wildtype Gastrointestinal Stromal Tumor Clinic

Jun 19, 2018

Join us on June 19 at 3:30 p.m. E.T. for a Facebook Live on the NIH Pediatric and Wildtype Gastrointestinal Stromal Tumor (GIST) Clinic. The GIST Clinic, which takes place June 20-22, is a collaborative effort between clinicians, research scientists and advocates who share the goal of helping young patients with gastrointestinal stromal tumors. Fernanda Arnaldez, M.D., a physician in the Division of Cancer Treatment and Diagnosis, and Margaret von Mehren, M.D., of Fox Chase Cancer Center will be joined by moderator Becky Owens of GIST Support International. Together they will discuss the GIST Clinic and its contributions to progressing GIST research. Read more...

Facebook Live: Pediatric and Wildtype Gastrointestinal Stromal Tumor Clinic
Cryo-EM

New cryo-EM images provide blueprint for drug development

Jun 18, 2018

In a recent collaborative study published in Nature, CCR researchers have visualized the interaction between two critical components of the body’s cellular communication network using cryo-electron microscopy (cryo-EM). The near-atomic resolution images provide a blueprint that could lead to more effective medications for cancer and other conditions. According to Sriram Subramaniam, Ph.D., Senior Investigator in the Laboratory of Cell Biology and a senior author of the study, “The use of cryo-EM technology to obtain structural information on important pharmaceutical targets such as GPCRs in various states demonstrates that we are now in a position to apply these methods for drug discovery applications.” Read more...

New cryo-EM images provide blueprint for drug development
hairy cell leukemia

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia

Jun 15, 2018

Findings from a phase III international clinical trial, led by Robert Kreitman, M.D., Senior Investigator in the Laboratory of Molecular Biology (LMB), show moxetumomab pasudotox (Moxe) may be an effective treatment option for patients with relapsed or refractory hairy cell leukemia (HCL). Initially developed by an LMB team led by Ira Pastan, M.D., Moxe is a toxin-based drug that can eliminate tiny deposits of cancer cells hiding in bone marrow – referred to as minimal residual disease. These deposits often avoid being killed by standard chemotherapy and are thought to be the cause of relapsed HCL. According to Dr. Kreitman, Moxe offers an option for HCL patients to avoid additional chemotherapy and may potentially improve long-term outcomes.  Read more...

Clinical trial suggests moxetumomab pasudotox may be an effective treatment for hairy cell leukemia
Travis at The Children's Inn

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1

Jun 15, 2018

Preliminary results from a phase II clinical trial at the Center for Cancer Research support the use of the investigational drug selumetinib for shrinking tumors in children and young adults with neurofibromatosis type 1 (NF1). NF1 is a genetic syndrome that often causes tumors, called plexiform neurofibromas, to develop in nerve cells on or under the skin. Although most of these tumors are not cancerous, patients commonly experience pain, reduced mobility and difficulty breathing. Results from the study, led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch, not only confirm findings from a smaller 2016 study demonstrating the drug’s ability to shrink large tumors, but also suggest the drug may improve symptoms. Read more...

Pediatric clinical trial supports use of selumetinib for children with neurofibromatosis type 1

Registration is now open for Frontiers in Basic Immunology: 2018 conference

Jun 14, 2018

This two-day national symposium addresses recent advances in the field of immunology and will be an exciting forum for discussion and debate on the current understanding of basic immunological mechanisms. Learn more...

Registration is now open for Frontiers in Basic Immunology: 2018 conference

Pages